Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Pipeline Review, H2 2017

Summary

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Retinoic Acid Receptor Alpha - Pipeline Review, H2 2017, outlays comprehensive information on the Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. It promotes the survival and development of early meiotic prophase spermatocytes. It regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5 and mediates retinoic acid-induced granulopoiesis.  The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 4, 4 and 1 respectively. Report covers products from therapy areas Dermatology, Oncology, Respiratory, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Batten Disease, Breast Cancer, Erythema Multiforme, Hormone Sensitive Breast Cancer, Inflammatory Bowel Disease, Myeloproliferative Disorders, Neutropenia, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Retinopathy Of Prematurity. 

Furthermore, this report also reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)
- The report reviews Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Overview 7
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 12
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Companies Involved in Therapeutics Development 20
3SBio Inc 20
Io Therapeutics Inc 20
Phosphagenics Ltd 20
Sol-Gel Technologies Ltd 21
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Drug Profiles 22
(benzoyl peroxide + tretinoin) - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
(clindamycin phosphate + tretinoin) - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
(gemfibrozil + tretinoin) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
alitretinoin - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
IRX-5183 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SBD-073 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
tamibarotene - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
TPX-6001 + tretinoin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
tretinoin - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
tretinoin - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
vitamin A palmitate - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
vitamin A palmitate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Dormant Products 44
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Discontinued Products 46
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Product Development Milestones 47
Featured News & Press Releases 47
Aug 31, 2017: Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress 47
Aug 21, 2017: Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML 47
Jul 21, 2017: Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients 48
Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris 49
Jun 23, 2017: Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients 50
May 18, 2017: Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients 51
May 08, 2017: Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARa Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference 52
May 04, 2017: Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer 53
May 01, 2017: Syros Participates in International Symposium to Support MDS Foundation's Efforts to Raise Awareness of Novel Therapies in Development for MDS 54
Apr 18, 2017: Syros to Present on SY-1425, Its First-in-Class Selective RARa Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference 54
Apr 04, 2017: Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARa Agonist, for Genomically Defined AML and MDS Patients 55
Mar 01, 2017: Syros to Present New Data on SY-1425 at Upcoming AACR Annual Meeting 56
Jan 09, 2017: Syros Pharma Outlines 2017 Strategic Goals, Provides Update On SY-1425 57
Dec 10, 2016: Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RARa Agonist in Genomically Defined Subsets of Breast Cancer 59
Dec 05, 2016: Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARa Agonist for Genomically Defined Subsets of AML and MDS Patients 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by 3SBio Inc, H2 2017 20
Pipeline by Io Therapeutics Inc, H2 2017 20
Pipeline by Phosphagenics Ltd, H2 2017 21
Pipeline by Sol-Gel Technologies Ltd, H2 2017 21
Dormant Products, H2 2017 44
Dormant Products, H2 2017 (Contd..1), H2 2017 45
Discontinued Products, H2 2017 46